- Home
- Publications
- Publication Search
- Publication Details
Title
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis
Authors
Keywords
-
Journal
CNS DRUGS
Volume 35, Issue 4, Pages 385-402
Publisher
Springer Science and Business Media LLC
Online
2021-04-02
DOI
10.1007/s40263-021-00798-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ozanimod: First Approval
- (2020) Yvette N. Lamb DRUGS
- The S1P–S1PR Axis in Neurological Disorders—Insights into Current and Future Therapeutic Perspectives
- (2020) Alexandra Lucaciu et al. Cells
- Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article
- (2020) Stanley Cohan et al. Biomedicines
- Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
- (2019) Newshan Behrangi et al. Cells
- The role of VE-cadherin in blood-brain barrier integrity under central nervous system pathological conditions
- (2018) Wenlu Li et al. Current Neuropharmacology
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
- (2018) Jeffrey A Cohen et al. Multiple Sclerosis Journal
- Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
- (2018) Tanuja Chitnis et al. NEW ENGLAND JOURNAL OF MEDICINE
- An update on sphingosine-1-phosphate receptor 1 modulators
- (2018) Alexander Marciniak et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Natalizumab-associated PML
- (2017) Nicholas Schwab et al. NEUROLOGY
- Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
- (2017) Burhan Z. Chaudhry et al. Neurotherapeutics
- Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation
- (2017) Veit Rothhammer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
- (2017) Ludwig Kappos et al. Multiple Sclerosis Journal
- Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
- (2016) Kunio Sugahara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
- (2016) F L Scott et al. BRITISH JOURNAL OF PHARMACOLOGY
- Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
- (2016) Antonietta Gentile et al. Journal of Neuroinflammation
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
- (2016) Ludwig Kappos et al. LANCET NEUROLOGY
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
- (2016) Ludwig Kappos et al. JAMA Neurology
- Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases
- (2016) Daniele D’Ambrosio et al. Therapeutic Advances in Chronic Disease
- Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
- (2015) Sonja Krösser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
- (2015) Jeffrey A Cohen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- Sphingosine 1-phosphate signaling at the blood–brain barrier
- (2015) Briana Prager et al. TRENDS IN MOLECULAR MEDICINE
- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications
- (2014) John Camm et al. AMERICAN HEART JOURNAL
- Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
- (2014) Alice Laroni et al. BMC Neurology
- New management algorithms in multiple sclerosis
- (2014) Per Soelberg Sorensen CURRENT OPINION IN NEUROLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- First-dose effects of fingolimod: Pooled safety data from three phase 3 studies
- (2014) John P. DiMarco et al. Multiple Sclerosis and Related Disorders
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study
- (2013) Patrick Brossard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Central Nervous System Herpes Simplex and Varicella Zoster Virus Infections in Natalizumab-Treated Patients
- (2013) A. J. Fine et al. CLINICAL INFECTIOUS DISEASES
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
- (2013) G Francis et al. Multiple Sclerosis Journal
- T-cell response against varicella-zoster virus in fingolimod-treated MS patients
- (2013) M. E. Ricklin et al. NEUROLOGY
- Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis
- (2013) Marco A. Zarbin et al. OPHTHALMOLOGY
- Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
- (2013) Shifeng Pan et al. ACS Medicinal Chemistry Letters
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis
- (2012) T. Komiya et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Prolonged and symptomatic bradycardia following a single dose of fingolimod
- (2012) Hans Faber et al. Multiple Sclerosis Journal
- Sudden unexpected death on fingolimod
- (2012) JW Lindsey et al. Multiple Sclerosis Journal
- Fingolimod-associated macular edema: Incidence, detection, and management
- (2012) N. Jain et al. NEUROLOGY
- Clinical Pharmacokinetics of Fingolimod
- (2011) Olivier J. David et al. CLINICAL PHARMACOKINETICS
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Delayed fingolimod-associated asystole
- (2011) Patricio S Espinosa et al. Multiple Sclerosis Journal
- Impact of sphingosine 1-phosphate modulation on immune outcomes
- (2011) D. D. Pinschewer et al. NEUROLOGY
- Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation
- (2011) T. Hla et al. NEUROLOGY
- Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis
- (2011) M. Mehling et al. NEUROLOGY
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
- (2010) M. Mehling et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure
- (2010) I. L. Grigorova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
- (2008) Carolyn A. Foster et al. BRAIN PATHOLOGY
- Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate
- (2008) Krishnan Venkataraman et al. CIRCULATION RESEARCH
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
- FTY720 modulates human oligodendrocyte progenitor process extension and survival
- (2007) Veronique E. Miron et al. ANNALS OF NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started